Close Menu
Business Voice NowBusiness Voice Now
    Facebook X (Twitter) Instagram
    Business Voice NowBusiness Voice Now
    Subscribe
    • Markets
      • IPO
      • Market News
    • Business
      • FMCG
      • Retail
      • Quick Commerce
      • Startups
    • Healthcare
    • Technology
    • Energy
    • Voices
      • Entrepreneur – CXO Stories
      • Corporate Office story
    • E Magazine
      • Year 2026
        • October 2026
        • September 2026
        • August 2026
        • July 2026
    Business Voice NowBusiness Voice Now
    Home»World»Philippines FDA approves first ever generic version of Pfizer anti-Covid pill
    World

    Philippines FDA approves first ever generic version of Pfizer anti-Covid pill

    By January 26, 2022No Comments2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    Follow Us
    Google News Flipboard Threads
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Manila (Philippines), January 25: The Philippines Food and Drug Administration (FDA) has approved the world’s first generic version of Pfizer’s anti-Coronavirus pill Paxlovid, just days after the original was granted Emergency Use Authorisation (EUA) by the US FDA.

    The Philippines FDA has approved the department of health’s application for a compassionate special permit application for the first generic version of Paxlovid that has been launched by Beximco Pharmaceuticals, a leading generic drugmaker from Bangladesh.

    Philippines-based Pharmaceutical company Biocare Lifesciences Inc would be the distributor and importer of a generic drug, which would be sold under the brand name Bexovid in the Philippines.

    According to Pfizer, the risk of hospitalisation or death is reduced by 89% when Paxlovid is given within three days of the onset of symptoms and by 88% when given within five days of the onset of symptoms. The treatment, a combination of Nirmatrelvir and Ritonavir tablets, is given together twice a day for five days and is recommended for treatment of mild to moderate cases of Covid-19.

    Pfizer data also suggests the drug remains effective against the faster-spreading Omicron variant of the Coronavirus, which is driving the latest surge in Covid-19 cases globally.

    “The approval by the Philippines FDA will make Bexovid accessible to Covid-19 patients in the country and add another treatment protocol to the existing drugs. We plan to import 20,000 to 30,000 courses of Bexovid initially and expect the supplies to begin in the first week of February. Bexovid is expected to be priced 50-60% cheaper than the original Pfizer drug, making it an affordable option,” said Dileep Tiwari, Managing Director, Biocare Lifesciences, during an interview with CNN.

    Bexovid is recommended as an at-home treatment to help reduce the severity of the infection. The drug has the potential to eliminate many hospitalizations, thus helping reduce the strain on the healthcare infrastructure.

    “Bexovid is not meant for patients who are hospitalised. Any patient who is Covid-19 positive can buy the drug from hospitals once supplies begin,” said Mr. Tiwari in a CNN interview.

    Separately, Bangladesh’s Directorate General of Drug Administration has also granted EUA for Bexovid to treat mild-to-moderate Covid-19 cases in patients aged 12 and above.

    world
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Starbucks closes underperforming stores in North America, announces first GCC in India amid push for profitability, efficiency

    September 26, 2026

    Pan IIT Alumni India Raises Red Flag Over World Wisdom Connect Event

    August 18, 2026

    Climate Change and Its Growing Toll on Agriculture and Food Supply

    July 9, 2026

    Comments are closed.

    Recent Post
    • Cordelia Cruises Crushes the Monsoon: Rs 585 Million Profit Blasts Past Last Year’s Loss
    • Love Marriage and Relationship Problems: Guidance from Astrologer Sonu Sharma
    • British Indian MP Shivani Raja, in India on Parliamentary Visit, Congratulates Prime Minister Narendra Modi on 25 Years as Head of Government
    • Central India’s Biggest Industrial Expo: ‘Plast Pack 2026’ to Showcase the Technology of the Future
    • Rathi Steel And Power Limited Q2 FY27 Revenue at Over Rs 200 Cr, Growth of Over 30% YoY; Sales Volume Growth at ~28.86% YoY
    • Not 40 years, but people who shaped the journey, Khushboo Rai makes ‘Chapter 40’ memorable
    • PRISM 2026 connected industry, government & education institutions to shape India’s future-ready logistics workforce
    • PH1 Industries, Specialised Engineering Solutions Provider, Files DRHP with NSE Emerge

    Type above and press Enter to search. Press Esc to cancel.